Drugs / Wobenzym
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00002311 | — | HIV infectious disease | Mucos Pharma GmbH and Co | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01916408 Comparator | Aug 2013 → Jan 2014 | blood coagulation disease, respiratory tract infectious disorder, sudden cardiac arrest | Technical University of Munich | Completed | No outcome recorded |
| — | NCT05038410 Comparator | Apr 2021 → Oct 2022 | osteoarthritis | Mucos Pharma GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wobenzym | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01916408 ↗ |
| Modality | Other / unclassified | “mixture of different enzymes and flavonoids (Wobenzym Plus®)” NCT01916408 ↗ |
| Route | Oral | “ingestion of oral hydrolytic enzymes and flavonoids” PMID 24559067 ↗ Feb 2014 |